{"product_id":"recombinant-human-tnf-alpha-tnfa-protein-aa-57-233-his-tag","title":"Recombinant Human TNF-alpha\/TNFA Protein (aa 57-233, His Tag)","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e: 50μg\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStorage\u003c\/b\u003e: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at \u0026lt; -20℃ for 3 months.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShipping\u003c\/b\u003e: This product is provided as lyophilized powder which is shipped with ice packs.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExp date\u003c\/b\u003e: 12 months\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCategory ID_II\u003c\/b\u003e: Recombinant Proteins\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCategory ID_III\u003c\/b\u003e: Cytokines\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAbbreviation\u003c\/b\u003e: TNF-alpha;TNFA\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Synonym\u003c\/b\u003e: Cachectin;TNF;TNF-Alpha;TNF-a;TNFA;TNFSF2;Tumor Necrosis Factor;Tumor Necrosis Factor Ligand Superfamily Member 2\u003c\/p\u003e\u003cp\u003e\u003cb\u003eResearch Areas\u003c\/b\u003e: Signal Transduction;Cardiovascular;Cancer;immunology;metabolism;\u003c\/p\u003e\u003cp\u003e\u003cb\u003eConjugation\u003c\/b\u003e: \u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Species\u003c\/b\u003e: Human\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExpression Host\u003c\/b\u003e: E.coli\u003c\/p\u003e\u003cp\u003e\u003cb\u003eApplication\u003c\/b\u003e: Cell culture\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFusion tag\u003c\/b\u003e: N-His\u003c\/p\u003e\u003cp\u003e\u003cb\u003eUNIProt ID\u003c\/b\u003e: P01375\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAccession\u003c\/b\u003e: P01375\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e: Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages; monocytes; neutrophils; T-cells; and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons; IL2; and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever; dose-limiting hypotension; hepatotoxicity; intravascular thrombosis; and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7; exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α; which binds to both murine TNF receptors. Based on these results; many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8; Lys9; Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eConcentration\u003c\/b\u003e: \u003c\/p\u003e\u003cp\u003e\u003cb\u003eActivity\u003c\/b\u003e: Measured in a cytotoxicity assay using L‑929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED\u003csub\u003e50\u003c\/sub\u003e for this effect is 30-150 pg\/ml. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eSequence\u003c\/b\u003e: Gly57-Leu233\u003c\/p\u003e\u003cp\u003e\u003cb\u003ePurity\u003c\/b\u003e:  \u0026gt; 95 % as determined by reducing SDS-PAGE.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFormulation\u003c\/b\u003e: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 100mM NaCl, pH 8.0.\u003cbr\u003eNormally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.\u003cbr\u003ePlease refer to the specific buffer information in the printed manual.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eReconstitution\u003c\/b\u003e: Please refer to the printed manual for detailed information.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eEndotoxin\u003c\/b\u003e:  \u0026lt; 1.0 EU per μg of the protein as determined by the LAL method.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCalculated MW\u003c\/b\u003e: 21.8 kDa\u003c\/p\u003e\u003cp\u003e\u003cb\u003eObservedMW\u003c\/b\u003e: 18 kDa\u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":47982486978660,"sku":"PKSH033165","price":81800.0,"currency_code":"JPY","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_f6a181ec-98ea-4aa0-8b01-d5a12026238b.jpg?v=1772386937","url":"https:\/\/www.genebiosystems.com\/en-jp\/products\/recombinant-human-tnf-alpha-tnfa-protein-aa-57-233-his-tag","provider":"GeneBio ","version":"1.0","type":"link"}